More Local, Less Global? New Oncology Guidelines Stress China Expertise, Social Values
Executive Summary
In an assertive move and significant departure from following the guidelines of the US and Europe, the China Society of Clinical Oncology issues its own set of cancer treatment guidelines with a clear focus on local conditions, patient access and use of China's own expertise.
You may also be interested in...
Lessons Learned And What's Ahead: I-Mab, JW, RemeGen CEOs On Biotech Financing
Top executives from three high-flying Chinese biotechs, all of which have gone public on Nasdaq and in Hong Kong, offered lessons learned and looked forward to what’s ahead in a panel session at the recent JPM conference.
China Approves Record New Cancer, Orphan Drugs In 2020 But Access Challenges Remain
Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?
China Rings In New Year With Major Deals, Record IPOs And Trends To Watch
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: